A cross-country utilization patterns comparison of high expenditure therapeutic groups between Portugal and six European countries: the two sides of the Portuguese coin

References

• Organization for Economic Cooperation and Development (OECD). Health at a Glance 2019. OECD Publishing, Paris: OECD Indicators; 2019. https://doi.org/10.1787/4dd50c09-en
   Google Scholar
• Morais Nunes A, Cunha Ferreira D, Campos Fernandes A. Financial crisis in Portugal: effects in the health care sector. Int J Health Serv. 2019;49(2):237–259.
   PubMed Web of Science ®Google Scholar
• Belloni A, Morgan D, Paris V (2016), ”Pharmaceutical Expenditure And Policies: Past Trends And Future Challenges”, OECD Health Working Papers, No. 87, OECD Publishing, Paris.
   Google Scholar
• da Saúde M, da Saúde R. Portugal 2018. 2018.
   Google Scholar
• Organization for Economic Cooperation and Development (OECD)/European Observatory on Health Systems and Policies. Portugal: Country Health Profile 2019, State of Health in the EU, OECD Publ. 2019. 1–24.
   Google Scholar
• INFARMED. Monitorização do consumo de medicamentos em meio ambulatório, 2020.
   Google Scholar
• Elseviers M, Wettermark B, Almarsdóttir AB, et al. Drug utilization research - methods and applications, Willey 2016.
   Google Scholar
• Health Market Research, Pharma Data – Pharmacy. n.d. [cited 2022 May 1]. Available from: https://www.hmr.co.com/pharmacy/
   Google Scholar
• Schmidt M, Hallas J, Laursen M, et al. Data resource profile: danish online drug use statistics (MEDSTAT). Int J Epidemiol. 2016;45:1401–02G.
   PubMed Web of Science ®Google Scholar
• Ferrer P, Ballarín E, Sabaté M, et al. On behalf of the PROTECT project. Drug consumption databases in Europe. Barcelona, February, 2015.
   Google Scholar
• Finnish Medicines Agency/Social Insurance Institution, Finnish Statistics on Medicines, (2019).
   Google Scholar
• Dutch Drug Information System (GIP) & National Health Care Institute. 2020. Available from: https://www.gipdatabank.nl/
   Google Scholar
• The Norwegian Institute of Public Health, Norwegian Prescription Database: prevalence statistics. 2020. Available from: http://www.norpd.no/Prevalens.aspx
   Google Scholar
• European Commission, Population on 1st January. Eurostat. 2019 [cited 2020 Apr 26]. Available from: https://ec.europa.eu/eurostat/databrowser/view/tps00001/default/table?lang=en
   Google Scholar
• Office for National Statistics, Population estimates, Home Off. 2019 [cited 2020 Oct 18]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates#timeseries
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology, WHOCC - ATC/DDD Index 2020. 2020 [cited 2020 Oct 1]. Available from: https://www.whocc.no/atc_ddd_index/
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2020, Oslo, Norway. 2020.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology, DDD Indicators. 2020 [cited 2020 Oct 21]. Available from: http://www.who.int/medicines/regulation/medicines-safety/toolkit_indicators/en/
   Google Scholar
• Organization for Economic Cooperation and Development (OECD). Gross domestic product (GDP) and spending, OECD Data. 2020 [cited 2020 May 10]. Available from: https://data.oecd.org/gdp/gross-domestic-product-gdp.htm
   Google Scholar
• Li E, Heran B, Wright J. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension (Review). 2014 [cited 2020 Apr 8]. Available from: https://doi.org/10.1002/14651858.CD009096.pub2.www.cochranelibrary.com
   Google Scholar
• Pinto D, Rodrigues AP, Nunes B. Initial therapeutic choices for hypertension in the Portuguese Sentinel Practice Network. Rev Port Cardiol. 2018;37:657–663.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE Guidel; 2019. www.nice.org.uk/guidance/ng136
   Google Scholar
• Taylor D, Davis M. Costs and benefits of ARBs in practice. Br J Cardiol. 2010;17:s14–s15.
   Google Scholar
• Direcção-Geral da Saúde, Abordagem Terapêutica da Hipertensão Arterial, Norma Da Direcção Geral Da Sauúde No 026/2011. 2011.
   Google Scholar
• Sociedade Europeia de Cardiologia, HIPERTENSÃO Recomendações da ESC/ESH para o Tratamento da Hipertensão Arterial. 2018.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al., 2018 ESC/ESH Guidelines for the management of arterial hypertension, 2018. DOI:10.1097/HJH.0000000000001961.
   Google Scholar
• Marques da Silva P, Lima MJ, Macedo Neves P, et al. Prevalência de fatores de risco cardiovascular e outras comorbilidades em doentes com hipertensão arterial assistidos nos Cuidados de Saúde Primários: estudo Precise. Rev Port Cardiol. 2019;38(6):427–437.
   PubMedGoogle Scholar
• Gaio V, Antunes L, Barreto M, et al. Prevalência de hipertensão arterial em Portugal: resultados do Primeiro Inquérito Nacional com Exame Físico (INSEF 2015). Bol Epidemiológico Inst Nac Saúde Dr Ricardo Jorge. 2018;22:29–33.
   Google Scholar
• Organization for Economic Cooperation and Development (OECD)/EU, Health at a Glance: Europe 2020, State of in the EU Cycle, 2020. DOI:10.1787/82129230-en.
   Google Scholar
• Torre C, Guerreiro J, De Oliveira Martins S, et al. Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time. Primary Care Diabetes. 2015;9:482–489.
   PubMed Web of Science ®Google Scholar
• Dores J. Insulinoterapia na diabetes mellitus tipo 2. Rev Port Cardiol. 2013;32:25–31.
   PubMedGoogle Scholar
• Dores J, Melo M. Insulinas em Portugal – questões Por Resolver. Rev Port Diabetes. 2018;13:34–40.
   Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41:2669–2701.
   PubMed Web of Science ®Google Scholar
• Gavina C, Heitor S. Resultados do Estudo DECLARE-TIMI 58 : um Ponto de Viragem no Tratamento da Diabetes Mellitus Tipo 2. Rev Port Diabetes. 2019;14(4):51–163.
   Google Scholar
• da Saúde D-G, Abordagem Terapêutica Farmacológica na Diabetes Mellitus Tipo 2 no Adulto, Norma Da Direção-Geral Da Saúde No 052/2011. 2015. 1–28.
   Google Scholar
• Bailey CJ, Day C. The future of new drugs for diabetes management. Diabet Res Clin Pract. 2019;155:107785.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;41(2020):255–323.
   Google Scholar
• Diabetes UK position statement, the future of the quality and outcomes framework in England. 2018 [cited 2021 Apr 13]. Available from: https://www.diabetes.org.uk/resources-s3/2018-08/Our%20position%20statement%20on%20the%20future%20of%20QOF%20in%20England.pdf
   Google Scholar
• Heintjes EM, Houben E, Beekman-Hendriks WL, et al. Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes. Neth J Med. 2019;77:317–329.
   PubMed Web of Science ®Google Scholar
• Direcção-Geral da Saúde, Insulinoterapia na Diabetes Mellitus tipo 2, Norma da Direcção Geral Da Sauúde No 025/2011. 2014. 1–11.
   Google Scholar
• Raposo JF. Diabetes: factos e Números 2016, 2017 e 2018. Rev Port Diabetes. 2020;15:19–27.
   Google Scholar
• Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388–1399.
   PubMed Web of Science ®Google Scholar
• Jones P, Kafonek S, Laurora I, et al. Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study). Am J Cardiol. 1998;81:582–587.
   PubMed Web of Science ®Google Scholar
• Toth PP, Banach M. Statins: then and now. Methodist Debakey Cardiovasc J. 2019;15:23–31.
   PubMedGoogle Scholar
• Pappa E, Rizos CV, Filippatos TD, et al. Emerging fixed-dose combination treatments for Hyperlipidemia. J Cardiovasc Pharmacol Ther. 2019;24(4):315–322.
   PubMed Web of Science ®Google Scholar
• Masana L, Ibarretxe D, Plana N. Reasons why combination therapy should be the new standard of care to achieve the LDL-Cholesterol targets: lipid-lowering combination therapy. Curr Cardiol Rep. 2020;22. DOI:10.1007/s11886-020-01326-w.
   PubMed Web of Science ®Google Scholar
• Stock JK. DA VINCI study: change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe. Atherosclerosis. 2020;314:74–76.
   PubMed Web of Science ®Google Scholar
• Cibelle Mariano MB, Antunes M, Rato Q. _e_LIPID: caracterização do perfil lipidico da população portuguesa. Inst Nac Saúde Bol Epidemiológico. 2015;14:7–10.
   Google Scholar
• Direcção-Geral da Saúde, Normas de Orientação Clínica – normas DGS. n.d. https://nocs.pt/
   Google Scholar
• Costa FM, Hemels MEW. Atrial fibrillation management: time for new goals. Rev Port Cardiol. 2020;39:663–665.
   PubMedGoogle Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42(2021):373–498.
   Google Scholar